Tag: Grifols

Brain Health Research

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study

/ by admin | Leave a Comment

This phase 2b/3 trial investigated the effects of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). In the study, 347 patients were randomized into three PE treatment groups with varying doses of albumin and intravenous immunoglobulin, or a placebo group. Treatment involved six weeks of weekly conventional PE, followed by […]

Read more

Brain Health Research

Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: Study design and progress

/ by admin | Leave a Comment

The AMBAR (Alzheimer Management By Albumin Replacement) study is a multicenter, randomized, placebo-controlled phase IIb/III trial investigating the effects of plasma exchange (PE) with therapeutic albumin replacement in patients with mild to moderate Alzheimer’s disease (AD). Previous studies indicated that PE with albumin may help remove amyloid-beta from plasma and cerebrospinal fluid, leading to improved […]

Read more

Brain Health Research

Results of Grifols’ AMBAR clinical trial published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

/ by admin | Leave a Comment

The results of Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show that plasma exchange with albumin replacement can slow Alzheimer’s disease progression. The therapy, which removes amyloid-beta protein bound to albumin from the blood, demonstrated benefits in cognitive and functional decline for […]

Read more

To top